MULTIPLE MYELOMA

This early-phase study tested a new drug called JNJ-64407564 in 15 Japanese patients with multiple myeloma that had come back or stopped responding to other treatments. The drug is a special antibody that helps the immune system attack cancer cells. The main goal was to check saf…

This study tested the drug denosumab in 55 people with multiple myeloma who also have kidney problems. The goal was to see if it could help manage bone damage caused by the cancer. Researchers measured changes in bone markers and watched for side effects like low calcium levels.

This study tested a cancer drug called isatuximab given either as a shot under the skin or through an IV, along with two other medicines (pomalidomide and dexamethasone), in 56 adults with multiple myeloma that had returned or stopped responding to prior treatments. The main goal…

This study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with different types of blood cancers like lymphoma and leukemia. The main goal was to check safety and see how well the treatment works. This is an early-stage study, so results help gui…

This study tested a combination of three drugs (lenalidomide, bortezomib, and dexamethasone) in 46 people newly diagnosed with multiple myeloma. The goal was to see how well the treatment shrank the cancer and how safe it was. Most patients had a good response, though some experi…

This study tested whether giving higher doses of carfilzomib along with lenalidomide and dexamethasone is safe and effective for people newly diagnosed with multiple myeloma. 29 participants received the drug combination to find the best tolerated dose and to measure how much can…

This study tested a combination of four drugs (carfilzomib, lenalidomide, dexamethasone, and elotuzumab) in 15 adults with multiple myeloma that had come back or stopped responding to treatment. The goal was to see how many patients achieved a very good partial response or better…

This early-stage study tested a combination of two drugs, acalabrutinib and ACP-319, in 40 people with B-cell cancers such as non-Hodgkin lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia. The goal was to check the safety and effectiveness of the drug pair. Part…

This study tested different doses and schedules of the drug belantamab mafodotin in 177 adults with multiple myeloma that had returned or not responded to at least three prior treatments. The goal was to see if changing the dose could reduce serious eye problems while still contr…

This study tested a multi-step treatment plan for 40 people under 70 with primary plasma cell leukemia, a rare and aggressive blood cancer. The approach included several rounds of different chemotherapy drugs, followed by a stem cell transplant using the patient's own cells, and …

This study tested a combination of three drugs (thalidomide, bortezomib, and high-dose melphalan) given before a stem cell transplant in 29 people with advanced multiple myeloma who had already tried a similar transplant. The goal was to find the safest dose of thalidomide and se…

This study looked at two different ways to treat multiple myeloma that has come back or not responded to treatment. All 23 participants first received a combination of clarithromycin, pomalidomide, and dexamethasone. Then, half got a stem cell transplant followed by pomalidomide …

This study tested a new drug called GPC-100 combined with propranolol, with or without another drug (G-CSF), to help collect stem cells from 30 people with multiple myeloma. The goal was to see if this combination could safely and effectively gather enough stem cells for an autol…

This study tested a new drug called TAK-079 when added to standard treatments for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The main goal was to find a safe dose and check for side effects. Fifty participants took part, and the results h…

This study tested a one-time treatment using the patient's own immune cells, engineered to target and kill myeloma cells. It involved 40 adults with multiple myeloma who had a weak response to a stem cell transplant and ongoing maintenance therapy. The goal was to see if this cel…

This study compared two different drug combinations for people newly diagnosed with multiple myeloma, a type of blood cancer. Over 1,500 patients aged 18-65 took part. The goal was to see which approach worked better at delaying the cancer's return, using a stem cell transplant a…

This study tested a new way of giving the drug elranatamab to people with multiple myeloma that returned or didn't respond to other treatments. The approach starts with very low doses and gradually increases them to reduce side effects. 86 participants received injections under t…

This study tested a new treatment called bb2121 in about 312 people with multiple myeloma, a type of blood cancer. It included patients whose cancer had returned or was hard to treat, as well as those at high risk. The goal was to see if bb2121 could shrink tumors or lead to remi…

This study tested a combination of three drugs (pomalidomide, dexamethasone, and carfilzomib) in 25 people whose multiple myeloma had returned or stopped responding to prior treatments. The goal was to find the safest dose and see how well the drugs worked together. Results helpe…

This study tested whether adding daratumumab to the standard drugs lenalidomide and dexamethasone helps people with newly diagnosed multiple myeloma live longer without their cancer getting worse. The trial included 737 adults who were not healthy enough for high-dose chemotherap…

This study tested a new version of the chemotherapy drug melphalan (EVOMELA) combined with fludarabine and total body irradiation before a half-matched (haploidentical) stem cell transplant in 43 adults with blood cancers like multiple myeloma. The goal was to see if this approac…

This study tested two different drug combinations to collect stem cells from 62 multiple myeloma patients before a stem cell transplant. The goal was to see which method worked better and caused fewer side effects. Results could help more patients successfully move forward with t…

This study tested a two-step treatment for multiple myeloma that came back after a stem cell transplant. First, patients received lenalidomide and dexamethasone to reduce the cancer and prepare the immune system. Then, they received infusions of immune cells from their original d…

This early-phase study tested a new treatment called C-CAR088 in 9 people with multiple myeloma that had returned or stopped responding to standard therapies. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The main goal was to check s…

This study offers continued treatment with elotuzumab and other drugs to 67 multiple myeloma patients who were already benefiting from these therapies in earlier trials but cannot yet get the drug commercially. The main goal is to track how long patients stay on treatment and mon…

This study tested whether adding the drug bortezomib to the standard chemotherapy before a donor stem cell transplant could help people with multiple myeloma live longer without their cancer getting worse. Fifty-four adults aged 18 to 69 with a suitable donor took part. The goal …

This study tested a new drug, daratumumab, added to two standard medicines (lenalidomide and dexamethasone) in 45 people whose multiple myeloma had returned or stopped responding to treatment. The goal was to check safety and see how many patients had their cancer shrink or disap…

This early-phase study tested an experimental drug called VS-6766, given by mouth on different schedules, in 104 adults with advanced solid tumors or multiple myeloma. The goal was to find a safe and tolerable dose, both when used alone and when combined with another drug (everol…

This study tested a combination of pomalidomide and dexamethasone in 63 patients with relapsed or refractory multiple myeloma who have specific high-risk genetic changes (deletion 17p or translocation 4;14). The goal was to see how well the treatment controls the disease and to c…

This phase 2 study tested a combination of three oral drugs (ixazomib, cyclophosphamide, and dexamethasone) as the first treatment for multiple myeloma in 12 newly diagnosed patients. The goal was to see if this all-oral regimen could control the disease effectively while causing…

This early-stage study tested a new drug called COM902, alone or with another drug (COM701), in 94 people with advanced cancers like ovarian, lung, colon, and multiple myeloma. The main goal was to check safety and find the best dose. While not a cure, the approach aims to contro…

This study tested whether a shot under the skin (subcutaneous) works as well as an intravenous (IV) infusion for the drug isatuximab in people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant. All participants also received standard chemotherapy d…

This study tested whether fasting for a longer period each night could help overweight or obese people with early signs of blood cancer (MGUS, smoldering multiple myeloma, or smoldering Waldenstrom macroglobulinemia) lose weight and possibly lower their cancer risk. Twenty-three …

This study tested the safety of the drug nivolumab, alone or combined with other drugs like daratumumab, in 320 people with blood cancers (lymphoma or multiple myeloma) that had returned or stopped responding to treatment. The main goal was to track serious side effects. This is …

This early-stage trial tested a new drug called cevostamab in 355 people with multiple myeloma that had returned or stopped responding to other treatments. The main goals were to check the drug's safety and find the right dose. Participants received the drug through an IV, and re…

This study tested a new medicine, elranatamab, in 39 Chinese adults with multiple myeloma that stopped responding to several standard treatments. The drug works by helping the body's immune system attack the cancer cells. The goal was to see if the drug is safe and can shrink or …

This study tested a new three-drug combination (ixazomib, cyclophosphamide, and dexamethasone) in 112 adults with multiple myeloma that had returned or stopped responding to three previous treatments. The goal was to see if adding ixazomib could help control the cancer longer. Pa…

This study tested a daily supplement of curcumin (from turmeric) and piperine (from black pepper) in 30 people with early-stage prostate cancer or the blood conditions MGUS and low-risk smoldering multiple myeloma. The goal was to see if the supplement could lower disease markers…

This study tested three different schedules of the drug daratumumab in 123 people with smoldering multiple myeloma, a condition that can turn into active cancer. The goal was to see which dose schedule works best to control the disease and prevent it from progressing. Participant…

This study tested a drug called daratumumab combined with dexamethasone in 64 people with multiple myeloma that had stopped responding to three other treatments. The goal was to see if the combination could shrink tumors and how safe it was. Results showed some patients responded…

This study tested a combined bone marrow and kidney transplant from a partially matched related donor for 10 people with both a blood disorder and chronic kidney disease. The goal was to treat both conditions and possibly reduce the need for lifelong anti-rejection drugs after th…

This study tested a combination of three drugs (carfilzomib, lenalidomide, and dexamethasone) in 55 people with high-risk smoldering multiple myeloma, a condition that often leads to active myeloma. The goal was to see if early treatment could reduce or eliminate cancer cells in …

This study tested a two-step treatment for multiple myeloma, a type of blood cancer. 148 patients received a first round of high-dose chemotherapy (melphalan) followed by a stem cell transplant, then a second round with melphalan plus another drug (bortezomib) and another transpl…

This early-phase study tested an experimental cell therapy called CC-95266 in 130 adults whose multiple myeloma had returned or stopped responding to standard treatments. The main goals were to check safety, find the best dose, and see if the therapy could shrink tumors. While no…

This study tested a combination of three drugs (pomalidomide, cyclophosphamide, and dexamethasone) in 100 adults with multiple myeloma whose cancer returned after initial treatment. Participants had previously received standard therapies including bortezomib and lenalidomide. The…

This study tested whether adding an experimental drug (CT-011) and a cancer vaccine to standard stem cell transplant is safe and helps prevent multiple myeloma from returning. 35 adults with myeloma received the combination after transplant. The goal was to boost the immune syste…

This early-stage trial tested a new cell therapy called FT576, given alone or with another drug (daratumumab), in 31 people with multiple myeloma that had returned or stopped responding to prior treatments. The main goals were to find safe doses and check for side effects. The st…

This early-phase study tested a combination of three drugs (ibrutinib, lenalidomide, and dexamethasone) in 14 adults with multiple myeloma that had returned or stopped responding to prior treatments. The main goal was to find safe doses and identify side effects. While the approa…

This study tested a treatment plan for 46 people newly diagnosed with multiple myeloma, a blood cancer. The plan included a drug combination (carfilzomib, lenalidomide, and dexamethasone) followed by a stem cell transplant, more drug therapy, and then long-term maintenance medica…

This study tested a drug called palifermin in 34 adults with blood cancers who received stem cell transplants from unrelated donors. The goal was to see if palifermin could reduce severe chronic graft-versus-host disease (GVHD), a serious complication where donor cells attack the…

This study tested whether adding daratumumab to two standard drugs (pomalidomide and dexamethasone) helps people with relapsed or refractory multiple myeloma live longer without their cancer getting worse. 304 adults who had already tried at least one prior treatment took part. T…

This study tested whether adding a drug called vorinostat to the usual combination of lenalidomide and dexamethasone could help people with multiple myeloma whose cancer had stopped responding to lenalidomide. The trial enrolled 25 patients and measured how many achieved at least…

This study tested an experimental drug called belantamab mafodotin in 221 adults with multiple myeloma that had returned or stopped responding to at least three prior treatments. Participants received one of two doses of the drug by IV infusion. The main goal was to see how many …

This early-phase study tested whether giving patients their own specially grown natural killer (NK) cells, combined with the drug bortezomib, is safe for people with advanced solid tumors or leukemia that no longer respond to standard treatments. 35 adults received increasing dos…

This study tested a two-step stem cell transplant using a drug called cyclophosphamide to lower the risk of graft-versus-host disease (GVHD) in people with high-risk blood cancers like leukemia and lymphoma. 47 patients received a transplant from a matched sibling donor. The goal…

This early-phase study tested a new drug called forimtamig in 225 people with multiple myeloma that returned or didn't respond to standard treatments. The goal was to check the drug's safety and find the right dose. Participants had no other good treatment options left.

This study tested a weekly dose of the drug carfilzomib combined with two standard chemotherapy drugs (melphalan and prednisone) in 32 older adults (65+) newly diagnosed with multiple myeloma. The goal was to find the safest dose and see how well the combination worked at shrinki…

This study tested a combination of four drugs (elotuzumab, carfilzomib, lenalidomide, and dexamethasone) in 46 people newly diagnosed with multiple myeloma, a blood cancer. The goal was to see how many patients achieved a very deep remission (stringent complete response or minima…

This study tested a new type of stem cell transplant for people with high-risk multiple myeloma, a serious blood cancer. Doctors used specially treated umbilical cord blood cells for the transplant, hoping this would reduce severe side effects while still fighting the cancer. The…

This early-stage study tested whether adding very high doses of vitamin C (ascorbic acid) to a low dose of chemotherapy (melphalan) is safe and might help control advanced multiple myeloma. It involved 6 patients whose cancer had returned or stopped responding to multiple prior t…

This study tested whether a structured educational program, called the Myeloma Pack Intervention, could improve quality of life for people with multiple myeloma. 85 patients received the program alongside their regular cancer treatment. The goal was to see if better understanding…

This small pilot study tested a 6-session rehabilitation program called Health Through Activity (HTA) in 5 adults with multiple myeloma who were on maintenance therapy and had trouble with daily activities due to their health. The program combined customized exercise with activit…

This study looked at whether starting supportive care (like counseling and symptom management) right after a multiple myeloma diagnosis helps improve quality of life compared to waiting 6 months. Twenty patients who were not eligible for stem cell transplant took part. Researcher…

This study tested a pain management program for 51 cancer survivors living in rural areas or who are Hispanic. The goal was to see if the program was easy to use and helpful for controlling cancer-related pain. Researchers measured how often participants used the program and how …

This study tested whether colesevelam, a medicine used for high cholesterol, could safely reduce diarrhea in people with multiple myeloma who take lenalidomide. 25 participants took colesevelam for 4 weeks. The goal was to see if their diarrhea improved to a mild level or better.

This study tested whether wearing special cooling caps during high-dose chemotherapy and stem cell transplant could prevent severe hair loss in people with multiple myeloma. 31 participants used Penguin cold caps, and researchers measured how much hair they kept. The goal was to …

This pilot study looked at whether distance Reiki—a hands-off energy therapy—could improve quality of life and immune function in 30 adults with multiple myeloma who had a stem cell transplant. Participants were randomly assigned to receive real Reiki, fake (sham) Reiki, or no ex…

This pilot study looked at whether providing plant-based, whole-food meals to multiple myeloma patients during stem cell transplant is practical and well-liked. The goal was to see if this diet could improve gut health, which is often damaged during treatment. 26 patients were en…

This study checked if three simple blood measurements—blood thickness, albumin/fibrinogen ratio, and red cell distribution width—can help predict how newly diagnosed multiple myeloma patients will do over one year. Researchers followed 48 patients for a year after diagnosis, comp…

This study measured certain proteins in the blood and urine of 20 adults newly diagnosed with multiple myeloma who were starting treatment with daratumumab. The goal was to see if these markers could help detect acute kidney injury early. Participants provided samples at the star…

This study looked at whether the COVID-19 vaccine triggers a strong immune response in people with multiple myeloma or Waldenstrom's macroglobulinemia. Researchers measured antibody levels 28 days after the final vaccine dose in 146 participants. The goal was to understand vaccin…

This study looked at nearly 1,900 male farmers over 50 to see if pesticides are linked to early signs of blood cancers like multiple myeloma. Researchers collected blood and urine samples and asked about pesticide use. No treatment was given—the goal was simply to gather informat…

This study surveyed 218 adults with chronic lymphocytic leukemia or multiple myeloma to learn about the financial difficulties they face from cancer treatment. Researchers asked patients about money problems over the past year and also surveyed doctors and clinics. The goal is to…

This study looked at 66 people with multiple myeloma to see how many also have a condition called autoimmune hemolytic anemia (AIHA), where the body attacks its own red blood cells. Researchers measured how often AIHA occurs and whether it affects the patient's outlook or respons…

This study looked at whether a substance in the blood called M-CSF can help doctors find bone damage caused by multiple myeloma. Researchers compared M-CSF levels in 111 people: those with multiple myeloma, those with a pre-cancer condition called MGUS, and healthy volunteers. Th…

This study looked at the genes of over 1,300 people with blood cancers like lymphoma, leukemia, and multiple myeloma. The goal was to find genetic patterns that could explain why some patients respond well to treatment while others do not. Researchers used stored tissue samples a…

This study followed 482 people with multiple myeloma in China who were already taking or about to start the drug Ninlaro as part of their normal care. The goal was to collect information on side effects and how the drug is used in everyday practice, not to test a new treatment. N…

This study looked at whether newer imaging techniques can better detect when early blood disorders (MGUS and smoldering myeloma) turn into active multiple myeloma. Thirty-one adults with these conditions received three types of scans: a standard PET/CT, an experimental PET/CT usi…

This study interviewed 9 people with multiple myeloma who had received at least 5 different treatments. The goal was to learn about their experiences and what matters most when making treatment decisions. No new drugs or therapies were tested; instead, the study focused on gather…